- Conditions
- Leukemia, Hodgkins Disease, Non-hodgkins Lymphoma, Myelodysplastic Syndrome
- Interventions
- Not listed
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Seattle, Washington
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 697–720
of 1,741
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Recurrent Colorectal Carcinoma, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer
- Interventions
- Fluorouracil, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Leucovorin Calcium, Panitumumab
- Drug · Other · Biological
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 4
- States / cities
- Duarte, California • Lancaster, California • Rancho Cucamonga, California + 1 more
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type
- Interventions
- Autologous Bone Marrow Transplantation, Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Ibrutinib, Laboratory Biomarker Analysis, Melphalan, Pharmacogenomic Study, Placebo Administration
- Procedure · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 280
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Tucson, Arizona + 202 more
- Conditions
- Acute Kidney Injury, Multiple Myeloma, Light Chain Nephropathy
- Interventions
- Daratumumab
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Pancreatic Neoplasms
- Interventions
- blood and bile
- Other
- Lead sponsor
- AdventHealth
- Other
- Eligibility
- 19 Years to 95 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Parkinson Disease, Parkinsonism
- Interventions
- Acute intermittent hypercapnic hypoxia (AIHH), Acute intermittent hypercapnic normoxia (AIHN)
- Other
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Gainesville, Florida
- Conditions
- Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Interventions
- Laboratory Biomarker Analysis, Ponatinib Hydrochloride, Quality-of-Life Assessment
- Other · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2030
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Dementia
- Interventions
- Clinical tau PET, Clinical amyloid test, Research blood collection, Cognitive assessments
- Diagnostic Test · Other
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 1,800 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Colorectal Cancer, Advanced Adenocarcinoma
- Interventions
- Signal-C™
- Device
- Lead sponsor
- Universal Diagnostics
- Industry
- Eligibility
- 45 Years to 84 Years
- Enrollment
- 12,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Raonoke, Virginia
- Conditions
- Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7
- Interventions
- Cetuximab, Intensity-Modulated Radiation Therapy, Ipilimumab, Laboratory Biomarker Analysis
- Biological · Radiation · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Adult Acute Lymphoblastic Leukemia in Complete Remission, Acute Myeloid Leukemia in Remission, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Childhood Acute Lymphoblastic Leukemia in Complete Remission
- Interventions
- Bone Marrow Transplantation, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Tacrolimus, Total Marrow Irradiation
- Procedure · Drug · Other + 1 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 12 Years to 60 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2025
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Breast Cancer
- Interventions
- polymorphism analysis, high performance liquid chromatography, laboratory biomarker analysis, radiomammography
- Genetic · Other · Procedure
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 180
- States / cities
- Augusta, Georgia • Aurora, Illinois • Bloomington, Illinois + 111 more
- Conditions
- Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
- Interventions
- Atezolizumab, Bevacizumab, Biospecimen Collection, Computed Tomography, Durvalumab, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Questionnaire Administration, Stereotactic Body Radiation Therapy, Tremelimumab
- Biological · Procedure · Other + 1 more
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 226 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2034
- U.S. locations
- 138
- States / cities
- Berkeley, California • Cameron Park, California • Fremont, California + 108 more
- Conditions
- Liver Transplant Recipients, Liver Transplantation
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Chicago, Illinois • New York, New York + 3 more
- Conditions
- Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
- Interventions
- Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21 Group 1), ficlatuzumab (BAML-16-001-S24), Azacitidine (BAML-16-001-S24), Venetoclax (BAML-16-001-S24), ZE46-0134 (BAML-16-001-S21 Group 2), Bleximenib (BAML-16-001-S25/HO181), Cytarabine (BAML-16-001-S25/HO181), Daunorubicin or Idarubicin (BAML-16-001-S25/HO181), Placebo (BAML-16-001-S25/HO181), Revumenib (BAML-16-001-S26/HO177), Placebo (BAML-16-001-S26/HO177)
- Biological · Other · Drug
- Lead sponsor
- Beat AML, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2032
- U.S. locations
- 31
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- FMP30 Donor Stool, Fecal Microbiota Transplantation (FMT) of FMP30 Donor Stool, Observational Control
- Drug · Procedure · Other
- Lead sponsor
- Jeffrey Gelfand
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Alzheimer Disease
- Interventions
- Not listed
- Lead sponsor
- Banner Health
- Other
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Pulmonary Nodule
- Interventions
- Blood collection, Chest Computed Tomography
- Procedure
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Nashville, Tennessee
- Conditions
- Osteoporosis, With or Without Treatment, Bisphosphonate Treatment, Atypical Femur Fracture, Bisphosphonate Related Osteonecrosis of the Jaws (BRONJ), Healthy Volunteers
- Interventions
- Not listed
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 314 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer
- Interventions
- bevacizumab, laboratory biomarker analysis
- Biological · Other
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 2
- States / cities
- Detroit, Michigan
- Conditions
- Squamous Cell Carcinoma
- Interventions
- Cisplatin, IMRT, Docetaxel, Cetuximab
- Drug · Radiation
- Lead sponsor
- Christopher Wilke
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2031
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Kidney Transplant Rejection, Immunosuppression
- Interventions
- TruGraf, Standard of Care
- Diagnostic Test · Other
- Lead sponsor
- Transplant Genomics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Mucopolysaccharidosis II
- Interventions
- No Intervention
- Other
- Lead sponsor
- Denali Therapeutics Inc.
- Industry
- Eligibility
- Up to 30 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 3
- States / cities
- Oakland, California • Chapel Hill, North Carolina • Pittsburgh, Pennsylvania
- Conditions
- Chronic Kidney Disease, Acute Kidney Injury
- Interventions
- 75 mg / 6 mL VFI™
- Device
- Lead sponsor
- FAST BioMedical
- Industry
- Eligibility
- 19 Years to 75 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama